Equites Radar

CLMT · Calumet, Inc

Specialty ChemicalsUnited StatesAnalyst view: Buy

$52.17

+5.81% last session

End-of-day data · close of 2026-10-26

Neutral2 bullish · 2 bearish technical signals
Consensus: Buy (2.33 from 5 analysts)
To mean target: +7.0%

Market cap

$5B

Enterprise value

$7B

Trailing P/E

—

Forward P/E

16.3

Dividend yield

0.0%

Beta

0.78

Avg volume

1M

Employees

2K

Daily Change %

5.81%

5 Days Change

5.78%

10 Days Change

-9.66%

30 Days Change

-2.76%

60 Days Change

9.26%

Month to Day Change

-2.89%

Year to Day Change

162.56%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)2.33
Covering analysts5
Mean price target$55.80
Low price target$40.00
Upside to mean target+7.0%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)44.0
50-day MA$53.72
200-day MA$37.94
Price vs 50-day MA-2.9%
Price vs 200-day MA+37.5%
MACD histogram-0.95
Volume vs 3-month avg1.1×
52w low $18.2252w high $59.05

Analyst sentiment over time — CLMT

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-09-02

Latest call per bank · past 12 months

UBS

Neutral

$47.00

-9.9% vs price
▲ raised from $26.00Maintains · 2026-08-25

Goldman Sachs

Neutral

$45.00

-13.7% vs price
▲ raised from $40.00Maintains · 2026-08-18

Recent rating actions

DateFirmActionRatingPrice target
2026-09-02HC Wainwright & Co.MaintainsBuy$60.00 → $75.00
2026-08-25UBSMaintainsNeutral$26.00 → $47.00
2026-08-18Goldman SachsMaintainsNeutral$40.00 → $45.00
2026-08-12TD CowenMaintainsHold$34.00 → $40.00
2026-07-30Goldman SachsMaintainsNeutral$36.00 → $40.00
2026-03-30HC Wainwright & Co.MaintainsBuy$33.00 → $60.00
2026-03-12Goldman SachsMaintainsBuy$24.00 → $34.00
2026-01-30Goldman SachsMaintainsBuy$20.00 → $24.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-10-26

  • neutral: RSI (14): RSI is 44 — neutral momentum, neither overbought nor oversold.
  • bearish: Price vs 50-day MA: Trading 2.9% below the 50-day MA ($53.72).
  • bullish: Price vs 200-day MA: Trading 37.5% above the 200-day MA ($37.94).
  • bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
  • bearish: MACD (12,26,9): MACD histogram is negative (-0.95) — short-term momentum is fading.
  • neutral: 52-week range: Price sits between the 52-week low ($18.22) and high ($59.05).

CLMT Price Chart

Loading chart for CLMT…

Fundamentals

Revenue (TTM)$5.0B
EBITDA$0M
Free cash flow$0M
Operating cash flow$0M
Book value / share$-12.94
Net Debt / EBITDA27.1
WACC8.0%
Revenue growth41.00%
Earnings growth—

About Calumet, Inc

Calumet, Inc. manufactures, formulates, and markets a slate of specialty branded products and renewable fuels in North America and internationally. It operates through Specialty Products and Solutions; Performance Brands; and Montana/Renewables segments. The Specialty Products and Solutions segment manufactures and markets various solvents, waxes, customized lubricating oils, white oils, petrolatums, gels, esters, and other products. The Montana/Renewables segment processes geographically advantaged renewable feedstocks into renewable diesel, aviation fuel, and renewable naphtha. This segment also engages in the process of Canadian crude oil into conventional gasoline, diesel, jet fuel, and specialty grades of asphalt. The Performance Brands segment blends, packages, and markets high performance products through Royal Purple, Bel-Ray, and TruFuel brands. It serves wholesale distributors and retail chains. Calumet, Inc. was founded in 1919 and is headquartered in Indianapolis, Indiana.

More in Specialty Chemicals

Screen CLMT against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.